Skip to main content
Ingo Mellinghoff, MD, Oncology, New York, NY, Memorial Sloan Kettering Cancer Center

IngoK.MellinghoffMDFACP

Oncology New York, NY

Department Chair, Memorial Sloan Kettering Cancer Center

Overview of Dr. Mellinghoff

Dr. Ingo Mellinghoff is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Technical University Munich Faculty of Medicine and has been in practice 24 years. He is one of 467 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1999 - 2004
  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterChief Residency, Internal Medicine, 1998 - 1999
  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1995 - 1998
  • Technical University Munich Faculty of Medicine
    Technical University Munich Faculty of MedicineClass of 1993

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1997 - 2025
  • NY State Medical License
    NY State Medical License 2008 - 2025

Awards, Honors, & Recognition

  • Member (elected) Association of American Physicians, 2020
  • Member (elected) American Society of Clinical Investigation, 2013

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Phase Ib of Copanlisib in Combination with Ibrutinib in Recurrent/Refractory Primary CNS Lymphoma (PCNSL)
    Ingo K Mellinghoff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • A phase I, open label, perioperative study of AG-120 and AG-881 in recurrent IDH1 mutant, low-grade glioma: Results from cohort 1. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018

Press Mentions

  • IU Researcher Leads National Work Focused on Developing Treatments for Inherited Childhood Cancers
    IU Researcher Leads National Work Focused on Developing Treatments for Inherited Childhood CancersNovember 18th, 2021
  • Global Coalition for Adaptive Research, Kazia, and Kintara Announce Commencement of Kazia’s Paxalisib and Kintara’s VAL-083 in GBM AGILE Trial
    Global Coalition for Adaptive Research, Kazia, and Kintara Announce Commencement of Kazia’s Paxalisib and Kintara’s VAL-083 in GBM AGILE TrialJanuary 6th, 2021
  • Kazia Executes Agreement to Commence GBM Agile Pivotal Study
    Kazia Executes Agreement to Commence GBM Agile Pivotal StudyOctober 16th, 2020
  • Join now to see all

Professional Memberships

Hospital Affiliations